Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
We are seeking a highly motivated, resourceful, and experienced Executive Assistant to support our Chief Financial Officer (CFO) and approximately 4–6 senior leaders within the organization. This is a highly visible role that requires exceptional organizational skills, sound judgment, discretion, communication excellence, and the ability to effectively manage multiple priorities in a fast-paced, collaborative environment.
What they're looking for
- 5+ years of experience supporting C-suite executives and senior leaders, including Vice Presidents and/or Senior Directors
- Experience working in the biotechnology or pharmaceutical industry required
- Experience supporting investor relations activities required
- Demonstrated success managing multiple priorities in a fast-paced environment with changing business needs
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs · San Francisco Bay Area